Patient lifetime value can make an acquisition analysis more representative than first-appointment revenue, but only when the practice can explain how the value was calculated. Decide whether the model uses collected revenue, billed charges, contribution margin, or another approved financial measure. Document which services are included, how write-offs and refunds are handled, how long the patient relationship is observed, and whether downstream referrals belong in the calculation.
The source uses $3,000 as an illustrative lifetime revenue figure. No supporting source URL for that amount appears in this JSON, so it should remain a source-preserved example rather than a verified benchmark for physician practices.
Build the practice model from auditable inputs. Estimate patient value over 2-3 years only if that observation window matches the practice's available data and the purpose of the analysis. Record the full SEO cost being evaluated, including the expenses stakeholders expect to count. Define which new patients qualify as organic under the attribution policy, and keep mixed-source or unresolved cases separate instead of assigning them to SEO for convenience.
Break-even is a calculation, not an outcome promise. Divide the cost under review by the approved patient-value input to estimate how many attributed patients would be required under that scenario. Then test the result against capacity, payer mix, collection, retention, and attribution uncertainty. A model that looks attractive only under one optimistic assumption should be labeled sensitive.
The source also describes its break-even example in words as a small number of new patients each month. Preserve the concept as an illustration, but do not convert it into a standard that another specialty or practice is expected to meet. The decision should use the practice's own economics.
Financial modeling does not determine medical, legal, privacy, or regulatory compliance. This content cannot guarantee compliance, and responsible legal, medical, compliance, and regulatory reviewers remain required for decisions within their scope.